Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

Strategic Financial Concepts LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 67.7% during the fourth quarter, according to the company in its most recent filing ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...

Eli Lilly and Company's latest 10-K report for the year ended December 31, 2024, reveals significant financial growth. The company reported a revenue of $45,042.7 million, marking a 32% increase from ...

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Lilly beat fourth-quarter estimates for earnings as well as sales. Sales of Lilly’s incretin medicines, Mounjaro, Trulicity and Zepbound, missed estimates, while that of non-incretin drugs like ...